       Document 0683
 DOCN  M9640683
 TI    Murine dendritic cells loaded in vitro with soluble protein prime
       cytotoxic T lymphocytes against tumor antigen in vivo [see comments]
 DT    9604
 AU    Paglia P; Chiodoni C; Rodolfo M; Colombo MP; Division of Experimental
       Oncology D, Istituto Nazionale per lo; Studio e la Cura dei Tumori,
       Milano, Italy.
 SO    J Exp Med. 1996 Jan 1;183(1):317-22. Unique Identifier : AIDSLINE
       MED/96136777
 CM    Comment in: J Exp Med 1996 Jan 1;183(1):7-11
 AB    The priming of an immune response against a major histocompatibility
       complex class I-restricted antigen expressed by nonhematopoietic cells
       involves the transfer of that antigen to a host bone marrow-derived
       antigen presenting cell (APC) for presentation to CD8+ T lymphocytes.
       Dendritic cells (DC), as bone marrow-derived APC, are first candidates
       for presentation of tumor-associated antigens (TAA). The aim of this
       study was to see whether DC are able to prime in vivo antigen-specific
       cytotoxic T lymphocytes after exposure to a soluble protein antigen in
       vitro. Lacking a well-defined murine TAA, we took advantage of
       beta-galactosidase (beta-gal)-transduced tumor cell lines as a model in
       which beta-gal operationally functions as TAA. For in vivo priming both
       a DC line, transduced or not transduced with the gene coding for murine
       GM-CSF, and fresh bone marrow-derived DC (bm-DC), loaded in vitro with
       soluble beta-gal, were used. Priming with either granulocyte macrophage
       colony-stimulating factor-transduced DC line or fresh bm-DC but not with
       untransduced DC line generated CTL able to lyse beta-gal-transfected
       target cells. Furthermore, GM-CSF was necessary for the DC line to
       efficiently present soluble beta-gal as an H-2Ld-restricted peptide to a
       beta-gal-specific CTL clone. Data also show that a long-lasting immunity
       against tumor challenge can be induced using beta-gal-pulsed bm-DC as
       vaccine. These results indicate that effector cells can be recruited and
       activated in vivo by antigen-pulsed DC, providing an efficient immune
       reaction against tumors.
 DE    beta-Galactosidase/IMMUNOLOGY  Animal  Bone Marrow/CYTOLOGY/IMMUNOLOGY
       Clone Cells/IMMUNOLOGY  CD8-Positive T-Lymphocytes/IMMUNOLOGY  Dendritic
       Cells/*IMMUNOLOGY  Female  Histocompatibility Antigens Class
       I/IMMUNOLOGY  Immunization Schedule  Lymphocyte Transformation  Mice
       Mice, Inbred BALB C  Neoplasms, Experimental/*THERAPY  Peptide
       Fragments/IMMUNOLOGY  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       Non-P.H.S.  T-Lymphocytes, Cytotoxic/*IMMUNOLOGY  *Vaccination
       Vaccines/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

